Literature DB >> 23147899

Systemic sclerosis--challenges for clinical practice.

Zsuzsanna H McMahan1, Laura K Hummers.   

Abstract

The management of patients with systemic sclerosis (SSc) can be challenging because disease-associated damage is often difficult to reverse and curative therapies are not yet available. Early identification and appropriate monitoring of patients with SSc is, therefore, critical so that active disease can be controlled and tissue damage prevented or delayed. However, early diagnosis of SSc is often difficult because the early clinical stages of the disease can be very similar to that of other autoimmune conditions. Screening for major organ manifestations of SSc, particularly interstitial lung disease, pulmonary hypertension, renal involvement and cardiac disease is a priority because involvement of these organs is associated with shorter life expectancies and early intervention might prevent disease progression. The prevention and management of digital ischaemia is also important as appropriate therapy often prevents substantial morbidity and functional loss. Treating gastrointestinal dysmotility can usually be managed using proton pump inhibitors and promotility agents, although in severe cases total parenteral nutrition is required. Calcinosis in patients with SSc is another common challenge that requires appropriate disease management and pain control. Each of these topics, which are relevant to both physicians and patients with SSc, are reviewed in further detail herein.

Entities:  

Mesh:

Year:  2012        PMID: 23147899     DOI: 10.1038/nrrheum.2012.191

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  132 in total

Review 1.  Scleroderma renal crisis.

Authors:  Virginia D Steen
Journal:  Rheum Dis Clin North Am       Date:  2003-05       Impact factor: 2.670

2.  A case of calcinosis universalis successfully treated with low-dose warfarin.

Authors:  Y Matsuoka; S Miyajima; N Okada
Journal:  J Dermatol       Date:  1998-11       Impact factor: 4.005

3.  Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort.

Authors:  S Emilie; C Goulvestre; A Bérezné; C Pagnoux; L Guillevin; L Mouthon
Journal:  Scand J Rheumatol       Date:  2011-05-30       Impact factor: 3.641

4.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors:  M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal:  Arthritis Rheum       Date:  1999-12

5.  Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

Authors:  Stephen C Mathai; Laura K Hummers; Hunter C Champion; Fredrick M Wigley; Ari Zaiman; Paul M Hassoun; Reda E Girgis
Journal:  Arthritis Rheum       Date:  2009-02

6.  Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.

Authors:  F M Wigley; R A Wise; J R Seibold; D A McCloskey; G Kujala; T A Medsger; V D Steen; J Varga; S Jimenez; M Mayes; P J Clements; S R Weiner; J Porter; M Ellman; C Wise; L D Kaufman; J Williams; W Dole
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

Review 7.  Pulmonary arterial hypertension complicating connective tissue diseases.

Authors:  Paul M Hassoun
Journal:  Semin Respir Crit Care Med       Date:  2009-07-24       Impact factor: 3.119

Review 8.  Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics.

Authors:  M Tonini; L Cipollina; E Poluzzi; F Crema; G R Corazza; F De Ponti
Journal:  Aliment Pharmacol Ther       Date:  2004-02-15       Impact factor: 8.171

Review 9.  Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma).

Authors:  H Sallam; T A McNearney; J D Z Chen
Journal:  Aliment Pharmacol Ther       Date:  2006-03-15       Impact factor: 8.171

Review 10.  Use and abuse of hydrogen breath tests.

Authors:  M Simrén; P-O Stotzer
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

View more
  11 in total

1.  [Calcinosis and scleroderma].

Authors:  Xavier Pujol Olivares
Journal:  Aten Primaria       Date:  2018-10-26       Impact factor: 1.137

2.  Management of gastrointestinal involvement in scleroderma.

Authors:  Vivek Nagaraja; Zsuzsanna H McMahan; Terri Getzug; Dinesh Khanna
Journal:  Curr Treatm Opt Rheumatol       Date:  2015-03-01

Review 3.  Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis.

Authors:  George Hung; Valentina Mercurio; Steven Hsu; Stephen C Mathai; Ami A Shah; Monica Mukherjee
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

Review 4.  Corticosteroids in Myositis and Scleroderma.

Authors:  Anna Postolova; Jennifer K Chen; Lorinda Chung
Journal:  Rheum Dis Clin North Am       Date:  2015-10-26       Impact factor: 2.670

5.  How does inflammation contribute to pulmonary hypertension?

Authors:  Rahul Kumar; Brian Graham
Journal:  Eur Respir J       Date:  2018-01-25       Impact factor: 16.671

6.  Systemic Sclerosis and Perceptions of Quality in Primary Care.

Authors:  Ashley L Toci; J Madison Hyer; Richard M Silver; Paul J Nietert; Faye N Hant
Journal:  Am J Med Sci       Date:  2016-02-17       Impact factor: 2.378

Review 7.  A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis.

Authors:  Timothy Kaniecki; Tsion Abdi; Zsuzsanna H McMahan
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-03-04       Impact factor: 4.991

8.  Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma.

Authors:  Jong-Sung Park; Yumin Oh; Yong Joo Park; Ogyi Park; Hoseong Yang; Stephanie Slania; Laura K Hummers; Ami A Shah; Hyoung-Tae An; Jiyeon Jang; Maureen R Horton; Joseph Shin; Harry C Dietz; Eric Song; Dong Hee Na; Eun Ji Park; Kwangmeyung Kim; Kang Choon Lee; Viktor V Roschke; Justin Hanes; Martin G Pomper; Seulki Lee
Journal:  Nat Commun       Date:  2019-03-08       Impact factor: 14.919

Review 9.  IL-17 in the rheumatologist's line of sight.

Authors:  Marie-Elise Truchetet; M Djavad Mossalayi; Katia Boniface
Journal:  Biomed Res Int       Date:  2013-07-25       Impact factor: 3.411

10.  Active subcutaneous calcinosis demonstrated by fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in a case of limited cutaneous systemic sclerosis.

Authors:  Manuela Vadrucci; Massimo Castellani; Riccardo Benti
Journal:  Indian J Nucl Med       Date:  2016 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.